Merus NV (FRA:2GH)
€ 48.8 1.4 (2.95%) Market Cap: 3.27 Bil Enterprise Value: 2.97 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 57/100

Merus NV to Discuss the Zeno Clinical Data and Provide a Program Update - Corporate Call Transcript

Jun 06, 2021 / 10:00PM GMT
Operator

Good day and thank you for standing by. Welcome to the Merus Investor Call.

(Operator Instructions) Thank you. And I would like to hand the conference over to your first speaker for today, Kathleen Farren. Thank you.

Please go ahead, ma'am.

Kathleen Farren
Merus N.V. - IR & Corporate Communications Officer

Good evening, everyone, and thank you for joining the Merus investor call to discuss our recently presented clinical data on zenocutuzumab or Zeno in NRG1 fusion cancers.

The slides we are presenting today are also available on the Investors & Media page of our website, www.merus.nl.

Before we get started on the call. We need to make some -- we will also be making certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans and events and circumstances that have not yet occurred, including but not limited to projections about Merus'

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot